Quavonlimab, a novel agent, represents a promising advance in targeted therapies. Its primary role involves specifically targeting with interleukin 15 , a cytokine vital for the longevity and growth of immune cells. By disrupting this interaction , quavonlimab effectively lowers IL-15-mediated , resulting in a decrease in excessive inflammation . T